Drug Database · Clinicians

Enoxaparin

Brands (38) Carcenoxar, Clexane, Enoxar…Show all

US brand (reference label): Lovenox; not a Philippine-registered brand.

Antithrombotic agents; Antithrombotic agets PH FDA category

Reduce dose if CrCl <30Rx · Prescription drug65 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 5017a927-2a24-4f27-89f9-27c805bf7d59, version date May 28, 2026 (Lovenox · Sanofi-Aventis U.S. LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness
  • Inpatient treatment of acute DVT with or without pulmonary embolism
  • Outpatient treatment of acute DVT without pulmonary embolism
  • Prophylaxis of ischemic complications of unstable angina and non–Q-wave myocardial infarction (MI)
  • Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with subsequent percutaneous coronary intervention (PCI)
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Lovenox is a low molecular weight heparin (LMWH) indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness (1.1) Inpatient treatment of acute DVT with or without pulmonary embolism (1.2) Outpatient treatment of acute DVT without pulmonary embolism (1.2) Prophylaxis of ischemic complications of unstable angina and non–Q-wave myocardial infarction (MI) (1.3) Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with subsequent percutaneous coronary intervention (PCI) (1.4) 1.1 Prophylaxis of Deep Vein Thrombosis Lovenox ® is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): in patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.1)] in patients undergoing hip replacement surgery, during and following hospitalization in patients undergoing knee replacement surgery in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness 1.2 Treatment of Acute Deep Vein Thrombosis Lovenox is indicated for: the inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium the outpatient treatment of acute deep vein thrombosis without pulmonary embolism, when administered in conjunction with warfarin sodium 1.3 Prophylaxis of Ischemic Complications of Unstable Angina and Non–Q-Wave Myocardial Infarction Lovenox is indicated for the prophylaxis of ischemic complications of unstable angina and non–Q-wave myocardial infarction, when concurrently administered with aspirin. 1.4 Treatment of Acute ST-Segment Elevation Myocardial Infarction Lovenox, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute ST-segment elevation myocardial infarction (STEMI) receiving thrombolysis and being managed medically or with percutaneous coronary intervention (PCI).

Contraindications

  • Active major bleeding
  • Immune-mediated HIT within the past 100 days or circulating antibodies
  • Hypersensitivity to enoxaparin, heparin or pork products
  • Hypersensitivity to benzyl alcohol (multiple-dose vials only)
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS Lovenox is contraindicated in patients with: Active major bleeding History of immune-mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies [see Warnings and Precautions (5.4)] Known hypersensitivity to enoxaparin sodium (e.g., pruritus, urticaria, anaphylactic/anaphylactoid reactions) [see Adverse Reactions (6.2)] Known hypersensitivity to heparin or pork products Known hypersensitivity to benzyl alcohol (which is in only the multiple-dose formulation of Lovenox) [see Warnings and Precautions (5.8)] Active major bleeding (4) History of heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies (4) Hypersensitivity to enoxaparin sodium (4) Hypersensitivity to heparin or pork products (4) Hypersensitivity to benzyl alcohol (for multiple-dose formulation only) (4)

Dosing: Adult

  • DVT prophylaxis, abdominal surgery: 40 mg SC once daily (first dose 2 hours before surgery), 7 to 10 days
  • DVT prophylaxis, hip or knee replacement: 30 mg SC every 12 hours, starting 12 to 24 hours after surgery
  • DVT prophylaxis, acutely ill medical patients: 40 mg SC once daily, 6 to 11 days
  • DVT with or without PE (treatment): 1 mg/kg SC every 12 hours, or 1.5 mg/kg SC once daily (inpatient)
  • Unstable angina / non-Q-wave MI: 1 mg/kg SC every 12 hours with aspirin
  • Acute STEMI (with aspirin): Under 75 years: 30 mg IV bolus plus 1 mg/kg SC, then 1 mg/kg SC every 12 hours (maximum 100 mg for the first two SC doses). 75 years and older: 0.75 mg/kg SC every 12 hours, no bolus (maximum 75 mg for the first two doses)
  • Kidney impairment: CrCl <30 mL/min: see kidney dosing (once-daily regimens)
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label

See full prescribing information for dosing and administration information. (2)

2.1 Pretreatment Evaluation

2.1 Pretreatment Evaluation Evaluate all patients for a bleeding disorder before starting Lovenox treatment, unless treatment is urgently needed.

2.2 Adult Dosage Abdominal Surgery

2.2 Adult Dosage Abdominal Surgery The recommended dose of Lovenox is 40 mg by subcutaneous injection once a day (with the initial dose given 2 hours prior to surgery) in patients undergoing abdominal surgery who are at risk for thromboembolic complications. The usual duration of administration is 7 to 10 days [see Clinical Studies (14.1)].

Hip or Knee Replacement Surgery The recommended dose of Lovenox is 30 mg every 12 hours administered by subcutaneous injection in patients undergoing hip or knee replacement surgery. Administer the initial dose 12 to 24 hours after surgery, provided that hemostasis has been established. The usual duration of administration is 7 to 10 days [see Clinical Studies (14.2)].

A dose of Lovenox of 40 mg once a day subcutaneously may be considered for hip replacement surgery for up to 3 weeks. Administer the initial dose 12 (±3) hours prior to surgery. Medical Patients during Acute Illness The recommended dose of Lovenox is 40 mg once a day administered by subcutaneous injection for medical patients at risk for thromboembolic complications due to severely restricted mobility during acute illness.

The usual duration of administration is 6 to 11 days [see Clinical Studies (14.3)]. Treatment of Deep Vein Thrombosis with or without Pulmonary Embolism The recommended dose of Lovenox is 1 mg/kg every 12 hours administered subcutaneously in patients with acute deep vein thrombosis without pulmonary embolism, who can be treated at home in an outpatient setting.

The recommended dose of Lovenox is 1 mg/kg every 12 hours administered subcutaneously or 1.5 mg/kg once a day administered subcutaneously at the same time every day for inpatient (hospital) treatment of patients with acute deep vein thrombosis with pulmonary embolism or patients with acute deep vein thrombosis without pulmonary embolism (who are not candidates for outpatient treatment). In both outpatient and inpatient (hospital) treatments, initiate warfarin sodium therapy when appropriate (usually within 72 hours of Lovenox).

Continue Lovenox for a minimum of 5 days and until a therapeutic oral anticoagulant effect has been achieved (International Normalization Ratio 2 to 3). The average duration of administration is 7 days [see Clinical Studies (14.4)]. Unstable Angina and Non–Q-Wave Myocardial Infarction The recommended dose of Lovenox is 1 mg/kg administered subcutaneously every 12 hours in conjunction with oral aspirin therapy (100 to 325 mg once daily) in patients with unstable angina or non–Q-wave myocardial infarction.

Treat with Lovenox for a minimum of 2 days and continue until clinical stabilization. The usual duration of treatment is 2 to 8 days [see Warnings and Precautions (5.2) and Clinical Studies (14.5)]. Treatment of Acute ST-Segment Elevation Myocardial Infarction The recommended dose of Lovenox is a single intravenous bolus of 30 mg plus a 1 mg/kg subcutaneous dose followed by 1 mg/kg administered subcutaneously every 12 hours (maximum 100 mg for the first two doses only, followed by 1 mg/kg dosing for the remaining doses) in patients with acute ST-segment elevation myocardial infarction.

Reduce the dosage in patients ≥75 years of age [see Dosage and Administration (2.4)]. Unless contraindicated, administer aspirin to all patients as soon as they are identified as having STEMI and continue dosing with 75 to 325 mg once daily. When administered in conjunction with a thrombolytic (fibrin specific or non–fibrin specific), administer Lovenox between 15 minutes before and 30 minutes after the start of fibrinolytic therapy.

The usual duration of Lovenox therapy is 8 days or until hospital discharge. For patients managed with percutaneous coronary intervention (PCI), if the last Lovenox subcutaneous administration was given less than 8 hours before balloon inflation, no additional dosing is needed. If the last Lovenox subcutaneous administration was given more than 8 hours before balloon inflation, administer an intravenous bolus of 0.3 mg/kg of Lovenox [see Warnings and Precautions (5.2)].

2.3 Dose Reduction for Patients with Severe Renal Impairment

2.3 Dose Reduction for Patients with Severe Renal Impairment The recommended prophylaxis and treatment dosage regimens for patients with severe renal impairment (creatinine clearance <30 mL/min) are described in Table 1 [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. Table 1: Dosage Regimens for Patients with Severe Renal Impairment (creatinine clearance <30 mL/minute) Indication Dosage Regimen Prophylaxis in abdominal surgery 30 mg administered subcutaneously once daily Prophylaxis in hip or knee replacement surgery 30 mg administered subcutaneously once daily Prophylaxis in medical patients during acute illness 30 mg administered subcutaneously once daily Inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium 1 mg/kg administered subcutaneously once daily Outpatient treatment of acute deep vein thrombosis without pulmonary embolism, when administered in conjunction with warfarin sodium 1 mg/kg administered subcutaneously once daily Prophylaxis of ischemic complications of unstable angina and non–Q-wave myocardial infarction, when concurrently administered with aspirin 1 mg/kg administered subcutaneously once daily Treatment of acute ST-segment elevation myocardial infarction in patients <75 years of age, when administered in conjunction with aspirin 30 mg single intravenous bolus plus a 1 mg/kg subcutaneous dose followed by 1 mg/kg administered subcutaneously once daily Treatment of acute ST-segment elevation myocardial infarction in geriatric patients ≥75 years of age, when administered in conjunction with aspirin 1 mg/kg administered subcutaneously once daily (no initial bolus) Although no dose adjustment is recommended in patients with creatinine clearance 30 to 50 mL/min and creatinine clearance 50 to 80 mL/min, observe these patients frequently for signs and symptoms of bleeding.

2.4 Recommended Dosage for Geriatric Patients with Acute ST-Segment Elevation Myocardial…

2.4 Recommended Dosage for Geriatric Patients with Acute ST-Segment Elevation Myocardial Infarction For treatment of acute ST-segment elevation myocardial infarction in geriatric patients ≥75 years of age, do not use an initial intravenous bolus. Initiate dosing with 0.75 mg/kg subcutaneously every 12 hours (maximum 75 mg for the first two doses only, followed by 0.75 mg/kg dosing for the remaining doses) [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3)].

No dose adjustment is necessary for other indications in geriatric patients unless kidney function is impaired [see Dosage and Administration (2.2)].

2.5 Administration

2.5 Administration Do not administer Lovenox by intramuscular injection. Administer Lovenox by intravenous or subcutaneous injection only. Lovenox is a clear, colorless to pale yellow sterile solution, and as with other parenteral drug products, should be inspected visually for particulate matter and discoloration prior to administration.

Use a tuberculin syringe or equivalent when using Lovenox multiple-dose vials to assure withdrawal of the appropriate volume of drug. Patients may self-inject by the subcutaneous route of administration only after their physicians determine that it is appropriate and with medical follow-up, as necessary. Provide proper training in subcutaneous injection technique before allowing self-injection (with or without the assistance of an injection device).

Subcutaneous Injection Technique Position patients in a supine position for Lovenox administration by deep subcutaneous injection. Do not expel the air bubble from the prefilled syringes before the injection, to avoid the loss of drug. Do not inject into skin that has bruises or scars. Do not inject through clothes. Alternate injection sites between the left and right anterolateral and left and right posterolateral abdominal wall.

Introduce the whole length of the needle into a skin fold held between the thumb and forefinger; hold the skin fold throughout the injection. To minimize bruising, do not rub the injection site after completion of the injection. Lovenox prefilled syringes and graduated prefilled syringes are for single, one-time use only and are available with a system that shields the needle after injection.

Remove the prefilled syringe from the packaging by peeling at the arrow as directed on the lid. Do not remove by pulling on the plunger as this may damage the syringe. Remove the needle shield by pulling it straight off the syringe (see Figure A). If less than the full syringe volume is needed to administer the prescribed dose, eject syringe contents until the prescribed dose is left in the syringe.

Figure A Inject using standard technique, pushing the plunger to the bottom of the syringe (see Figure B). Figure B Remove the syringe from the injection site keeping your finger on the plunger rod (see Figure C). Figure C Orient the needle away from you and others, and activate the safety system by firmly pushing the plunger rod.

The protective sleeve will automatically cover the needle and an audible "click" will be heard to confirm shield activation (see Figure D). Figure D Immediately dispose of the syringe in the nearest sharps container (see Figure E). Figure E NOTE: The safety system can only be activated once the syringe has been emptied. Activation of the safety system must be done only after removing the needle from the patient's skin.

Do not replace the needle shield after injection. The safety system should not be sterilized. Activation of the safety system may cause minimal splatter of fluid. For optimal safety, activate the system while orienting it downwards away from yourself and others. Figure A Figure B Figure C Figure D Figure E Intravenous (Bolus) Injection Technique Use the multiple-dose vial for intravenous injections.

Administer Lovenox through an intravenous line. Do not mix or coadminister Lovenox with other medications. Flush the intravenous access device with a sufficient volume of saline or dextrose solution prior to and following the intravenous bolus administration of Lovenox, to prevent mixing of drugs. Lovenox is compatible with normal saline solution (0.9%) or 5% dextrose in water.

2.6 Monitoring for Safety

2.6 Monitoring for Safety During therapy monitor complete blood counts including platelets and stool occult blood. Assess for signs and symptoms of bleeding. In patients with renal impairment anti-Factor Xa levels may be used to monitor the anticoagulant effects of Lovenox. If during Lovenox therapy abnormal coagulation parameters or bleeding should occur, anti-Factor Xa levels may be used to monitor the anticoagulant effects of Lovenox [see Clinical Pharmacology (12.3)].

Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) are not adequate for monitoring the anticoagulant effects of Lovenox.

Dosing: Altered kidney function

Enoxaparin exposure rises in kidney impairment. The US label reduces doses when creatinine clearance (CrCl) is below 30 mL/min, mostly to once-daily regimens, and recommends no adjustment at CrCl 30 mL/min or higher.

Kidney function measure: Label uses creatinine clearance (CrCl, mL/min).

Show full dosing details
CrCl ≥60 mL/min
Usual dosing (label: no adjustment at CrCl 50 to 80).
CrCl 30–59 mL/min
No dose adjustment (label: CrCl 30 to <50 and 50 to 80); observe for bleeding.
CrCl 15–29 mL/min
Prophylaxis (abdominal surgery, hip or knee replacement, acutely ill medical patients): 30 mg SC once daily. Deep vein thrombosis (DVT) treatment, unstable angina/non-Q-wave myocardial infarction (MI): 1 mg/kg SC once daily. ST-elevation MI under 75 years: 30 mg IV bolus plus 1 mg/kg SC, then 1 mg/kg SC once daily; 75 years and older: 1 mg/kg SC once daily, no bolus (label).
CrCl <15 mL/min (not on dialysis)
Use the CrCl <30 regimens (label). The label gives no separate data below CrCl 15; accumulation risk is highest here, so seek specialist input (clinical judgment; anti-factor Xa monitoring or unfractionated heparin may be preferred).
Hemodialysis (intermittent)
No dosing in label. A single-dose study showed about 2-fold higher exposure in hemodialysis patients (label). Insufficient data: avoid or use with specialist input (consider anti-factor Xa monitoring).
Peritoneal dialysis
No data in label. Insufficient data: specialist input.
CRRT
No data in label. Insufficient data: specialist input.
  • Dialyzable? Not stated in label.
  • Monitoring Signs of bleeding in all kidney impairment; platelet count (heparin-induced thrombocytopenia); potassium (hyperkalemia reported in renal failure) (label). Low body weight (women <45 kg, men <57 kg) raises exposure: observe closely for bleeding (label).
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Not established in children.
eGFR 30–59
Not established in children.
eGFR 15–29
Not established in children.
eGFR <15 (not on dialysis)
Not established in children.
Hemodialysis (intermittent)
Not established in children.
Peritoneal dialysis
Not established in children.
CRRT
Not established in children.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

2.3 Dose Reduction for Patients with Severe Renal Impairment The recommended prophylaxis and treatment dosage regimens for patients with severe renal impairment (creatinine clearance <30 mL/min) are described in Table 1 [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. Table 1: Dosage Regimens for Patients with Severe Renal Impairment (creatinine clearance <30 mL/minute) Indication Dosage Regimen Prophylaxis in abdominal surgery 30 mg administered subcutaneously once daily Prophylaxis in hip or knee replacement surgery 30 mg administered subcutaneously once daily Prophylaxis in medical patients during acute illness 30 mg administered subcutaneously once daily Inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium 1 mg/kg administered subcutaneously once daily Outpatient treatment of acute deep vein thrombosis without pulmonary embolism, when administered in conjunction with warfarin sodium 1 mg/kg administered subcutaneously once daily Prophylaxis of ischemic complications of unstable angina and non–Q-wave myocardial infarction, when concurrently administered with aspirin 1 mg/kg administered subcutaneously once daily Treatment of acute ST-segment elevation myocardial infarction in patients <75 years of age, when administered in conjunction with aspirin 30 mg single intravenous bolus plus a 1 mg/kg subcutaneous dose followed by 1 mg/kg administered subcutaneously once daily Treatment of acute ST-segment elevation myocardial infarction in geriatric patients ≥75 years of age, when administered in conjunction with aspirin 1 mg/kg administered subcutaneously once daily (no initial bolus) Although no dose adjustment is recommended in patients with creatinine clearance 30 to 50 mL/min and creatinine clearance 50 to 80 mL/min, observe these patients frequently for signs and symptoms of bleeding.

8.7 Renal Impairment In patients with renal impairment, there is an increase in exposure of enoxaparin sodium. All such patients should be observed carefully for signs and symptoms of bleeding. Because exposure of enoxaparin sodium is significantly increased in patients with severe renal impairment (creatinine clearance <30 mL/min), a dosage adjustment is recommended for therapeutic and prophylactic dosage ranges.

No dosage adjustment is recommended in patients with creatinine clearance 30 to <50 mL/min and creatinine clearance 50 to 80 mL/min [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)]. In patients with renal failure, treatment with Lovenox has been associated with the development of hyperkalemia [see Adverse Reactions (6.2)].

Dosing: Pediatric

Approved ages
Safety and effectiveness not established in pediatric patients; not approved for neonates or infants (label).
Usual dose
Not established.
Maximum dose
Not applicable.
Neonates
Neonates: not approved. Multiple-dose vials contain benzyl alcohol (gasping syndrome risk in premature neonates) (label).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness of Lovenox in pediatric patients have not been established. Lovenox is not approved for use in neonates or infants. Serious adverse reactions including fatal reactions and the "gasping syndrome" occurred in premature neonates and low-birth-weight infants in the neonatal intensive care unit who received drugs containing benzyl alcohol as a preservative.

In these cases, benzyl alcohol dosages of 99 to 234 mg/kg/day produced high levels of benzyl alcohol and its metabolites in the blood and urine (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/L). Additional adverse reactions included gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse.

Preterm, low-birth-weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known. Lovenox multiple-dose vials contain 15 mg/mL of benzyl alcohol (at the dose of 1.5 mg/kg twice a day, benzyl alcohol exposure in patients is 0.45 mg/kg daily) [see Warnings and Precautions (5.8)].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Prevention of Deep Vein Thrombosis in Hip, Knee and Abdominal Surgery; Treatment of Deep Vein Thrombosis, Prevention of Ischemic Complications of Unstable Angina and Non–Q-Wave Myocardial Infarction Over 2800 patients, 65 years and older, have received Lovenox in clinical trials. The efficacy of Lovenox in the geriatric (≥65 years) was similar to that seen in younger patients (<65 years).

The incidence of bleeding complications was similar between geriatric and younger patients when 30 mg every 12 hours or 40 mg once a day doses of Lovenox were employed. The incidence of bleeding complications was higher in geriatric patients as compared to younger patients when Lovenox was administered at doses of 1.5 mg/kg once a day or 1 mg/kg every 12 hours.

The risk of Lovenox-associated bleeding increased with age. Serious adverse events increased with age for patients receiving Lovenox. Other clinical experience (including postmarketing surveillance and literature reports) has not revealed additional differences in the safety of Lovenox between geriatric and younger patients.

Careful attention to dosing intervals and concomitant medications (especially antiplatelet medications) is advised. Lovenox should be used with care in geriatric patients who may show delayed elimination of enoxaparin. Monitoring of geriatric patients with low body weight (<45 kg) and those predisposed to decreased renal function should be considered [see Warnings and Precautions (2.6) and Clinical Pharmacology (12.3)].

Treatment of Acute ST-Segment Elevation Myocardial Infarction In the clinical study for treatment of acute ST-segment elevation myocardial infarction, there was no evidence of difference in efficacy between patients ≥75 years of age (n=1241) and patients less than 75 years of age (n=9015). Patients ≥75 years of age did not receive a 30 mg intravenous bolus prior to the normal dosage regimen and had their subcutaneous dose adjusted to 0.75 mg/kg every 12 hours [see Dosage and Administration (2.4)].

The incidence of bleeding complications was higher in patients ≥65 years of age as compared to younger patients (<65 years).

Administration

2.5 Administration Do not administer Lovenox by intramuscular injection. Administer Lovenox by intravenous or subcutaneous injection only. Lovenox is a clear, colorless to pale yellow sterile solution, and as with other parenteral drug products, should be inspected visually for particulate matter and discoloration prior to administration. Use a tuberculin syringe or equivalent when using Lovenox multiple-dose vials to assure withdrawal of the appropriate volume of drug. Patients may self-inject by the subcutaneous route of administration only after their physicians determine that it is appropriate and with medical follow-up, as necessary. Provide proper training in subcutaneous injection technique before allowing self-injection (with or without the assistance of an injection device). Subcutaneous Injection Technique Position patients in a supine position for Lovenox administration by deep subcutaneous injection. Do not expel the air bubble from the prefilled syringes before the injection, to avoid the loss of drug. Do not inject into skin that has bruises or scars. Do not inject through clothes. Alternate injection sites between the left and right anterolateral and left and right posterolateral abdominal wall. Introduce the whole length of the needle into a skin fold held between the thumb and forefinger; hold the skin fold throughout the injection. To minimize bruising, do not rub the injection site after completion of the injection. Lovenox prefilled syringes and graduated prefilled syringes are for single, one-time use only and are available with a system that shields the needle after injection. Remove the prefilled syringe from the packaging by peeling at the arrow as directed on the lid. Do not remove by pulling on the plunger as this may damage the syringe. Remove the needle shield by pulling it straight off the syringe (see Figure A ). If less than the full syringe volume is needed to administer the prescribed dose, eject syringe contents until the prescribed dose is left in the syringe. Figure A Inject using standard technique, pushing the plunger to the bottom of the syringe (see Figure B ). Figure B Remove the syringe from the injection site keeping your finger on the plunger rod (see Figure C ). Figure C Orient the needle away from you and others, and activate the safety system by firmly pushing the plunger rod. The protective sleeve will automatically cover the needle and an audible "click" will be heard to confirm shield activation (see Figure D ). Figure D Immediately dispose of the syringe in the nearest sharps container (see Figure E ). Figure E NOTE: The safety system can only be activated once the syringe has been emptied. Activation of the safety system must be done only after removing the needle from the patient's skin. Do not replace the needle shield after injection. The safety system should not be sterilized. Activation of the safety system may cause minimal splatter of fluid. For optimal safety, activate the system while orienting it downwards away from yourself and others. Figure A Figure B Figure C Figure D Figure E Intravenous (Bolus) Injection Technique Use the multiple-dose vial for intravenous injections. Administer Lovenox through an intravenous line. Do not mix or coadminister Lovenox with other medications. Flush the intravenous access device with a sufficient volume of saline or dextrose solution prior to and following the intravenous bolus administration of Lovenox, to prevent mixing of drugs. Lovenox is compatible with normal saline solution (0.9%) or 5% dextrose in water.

US FDA label

Dosage forms

Philippines

  • Solution for injection: 40 mg/0.4 mL, 60 mg/0.6 mL, 2,000 IU (equivalent to 20 mg)/0.2 mL, 2,000 IU Anti-Factor Xa (equivalent to 20 mg)/0.2 mL, 4,000 IU (equivalent to 40 mg)/0.4 mL, 4000 IU Anti-Factor Xa (Equivalent to 40 mg)/0.4 mL, 6000 IU (equivalent to 60 mg)/0.6 mL, 6000 IU Anti-factor Xa (equivalent to 60 mg)/0.6 mL
  • ) solution for injection: 4000 IU/0.4 mL (40 mg/0.4 mL, 6,000 IU/0.6 mL (60 mg/0.6 mL, 6000 IU/0.6 mL (60 mg/0.6 mL

Registered products in the Philippines

65 products registered with the Food and Drug Administration (FDA) Philippines list Enoxaparin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products65
Philippine FDA-registered products for Enoxaparin
Package insert
Bicanoxen 40Enoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Altomed Pharmaceuticals, Inc.Importer: Ambica International Corporation
BRP-041-21
Dec 9, 2030
BnoxaparinEnoxaparin sodium
2,000 IU Anti-Factor Xa (equivalent to 20 mg) / 0.2 mL Solution for Injection (IV/SC)Pre-filled Syringe in Mono Blister (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Ambica International Corporation
BRP-063
Aug 15, 2038
Bnoxaparin 40Enoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL pre-filled syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Ambica International Corporation
BRP-041
Dec 9, 2030
CarcenoxarEnoxaparin sodium
2,000 IU Anti-Factor Xa (equivalent to 20 mg)/ 0.2 mL Solution for Injection (IV/SC)Pre-filled Syringe in Mono Blister (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
AGCC MarketingImporter: Ambica International Corporation
BRP-063-02
Aug 1, 2037
CarcenoxarEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
AGCC MarketingImporter: Ambica International Corporation
BRP-041-19
Dec 9, 2030
CarcenoxarEnoxaparin sodium
6000 IU Anti-Factor Xa (Equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
BRP-040-18
Jul 20, 2031
ClexaneEnoxaparin (as sodium)
2,000 IU (equivalent to 20 mg)/0.2 mL Solution for Injection (SC)0.2 mL in 0.5 mL Pre-filled Glass Syringe with Needle (without safety system) and/or 0.2 mL in 0.5 mL Pre-filled Glass Syringe with safety system (Eris or Preventis) (Box of 1's and 2's)
Rx
Sanofi Winthrop IndustrieFrance
Importer: Sanofi-Aventis Philippines, Inc.
BR-799
Apr 15, 2031
ClexaneEnoxaparin (as sodium)
4,000 IU (equivalent to 40 mg)/0.4 mL Solution for Injection (SC)0.4 mL in 0.5 mL Pre-filled Glass Syringe with Needle (without safety needle) and/or 0.4 mL in 0.5 mL Pre-filled Glass Syringe with safety system (Eris or Preventis) (Box of 1's and 2's)
Rx
Sanofi Winthrop IndustrieFrance
Importer: Sanofi-Aventis Philippines, Inc.
BR-797
Apr 15, 2031
ClexaneEnoxaparin sodium
6000 IU (equivalent to 60 mg)/0.6 mL Solution for Injection (S.C)0.6 mL in 1 mL pre-filled glass syringe with needle (without safety system) and/or 0.6 mL in 1 mL pre-filled glass syringe with safety system (Eris or Preventis) (Box of 1's and 2's)
Rx
Sanofi Winthrop IndustrieFrance
Sanofi-Aventis Philippines, Inc.
BR-798
Apr 15, 2031
CoranoxEnoxaparin sodium
4000 IU anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Macropharma CorporationImporter: Ambica International Corporation
BRP-041-13
Dec 9, 2030
CoranoxEnoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Macropharma CorporationImporter: Ambica International Corporation
BRP-040-12
Jul 14, 2031
DynaxaparinEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Dynasty PharmaceuticalsImporter: Ambica International Corporation
BRP-041-14
Dec 9, 2030
DynaxaparinEnoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1)
Rx
Brawn Laboratories LimitedIndia
Dynasty PharmaceuticalsImporter: Ambica International Corporation
BRP-040-14
Apr 16, 2037
EmoxinEnoxaparin sodium
6,000 IU/0.6 mL (60 mg/0.6 mL) Solution for Injection (SC)0.6 mL Borosilicate Glass Pre-filled Syringe with Rubber Stopper and Plunger Rod (Box of 2's)
Rx
Hangzhou Jiuyuan Gene Engineering Co. Ltd.China
Amson PharmaceuticalsImporter: Sahar International Trading, Inc.
BRP-097-01
Mar 30, 2031
EnoclexEnoxaparin Sodium
40 mg/0.4 mL Solution for Injection (SC)Type I pre-filled glass syringe x 0.4 mL with needle, packed in PVC/PE/paper blister (Box of 2's)
Rx
Shenzhen Techdow Pharmaceutical Co., Ltd.China
Importer: Endure Medical, Inc.
BR-939
Apr 14, 2029
EnoclexEnoxaparin Sodium
60mg/0.6 mL Solution for Injection (SC)Type I pre-filled glass syringe x 0.6 mL with needle packed in PVC/PE/Paper Blister (Box of 2's)
Rx
Shenzhen Techdow Pharmaceutical Co., Ltd.China
Endure Medical Inc.
BR-909
May 21, 2028
EnomaxEnoxaparin sodium
40 mg/0.4 mL Solution for Injection (IV/SC)0.4 mL-net content in a 1 mL-capacity Type I pre-filled glass syringe with black bromobutyl rubber stopper, polypropylene plunger rod and 27 gauge stainless steel needle (Box of 2's).
Rx
Nanjing King Friend Company LimitedChina
Goodfellow Pharma Corporation
BR-1495
Aug 5, 2030
EnomaxEnoxaparin sodium
60 mg/0.6 mL Solution for Injection (IV/SC)0.6 mL-net content in a 1 mL-capacity Type I pre-filled glass syringe with black bromobutyl rubber stopper, polypropylene plunger rod and 27 gauge stainless steel needle (Box of 2's).
Rx
Nanjing King Friend Biochemical Company LimitedChina
Goodfellow Pharma Corporation
BR-1496
Aug 5, 2030
EnoxarEnoxaparin sodium
2,000 IU Anti-Factor Xa (equivalent to 20 mg)/ 0.2 mL Solution for Injection (IV/SC)Pre-filled Syringe in Mono Blister (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Uni-Pharma Phils., Inc.Importer: Ambica International Corporation
BRP-063-03
Jul 11, 2037
EnoxarEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Uni-Pharma Phils., Inc.Importer: Ambica International Corporation
BRP-041-20
Dec 9, 2030
EnoxarEnoxaparin sodium
6000 IU Anti-Factor Xa (Equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1)
Rx
Brawn Laboratories LimitedIndia
Uni-Pharma Phils., Inc.Importer: Ambica International Corporation
BRP-040-19
Apr 16, 2037
Enoxbasy 40Enoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
BRP-041-07
Dec 9, 2030
Enoxbasy 60Enoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1)
Rx
Brawn Laboratories LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
BRP-040-05
Mar 31, 2037
Enoxbicare-40Enoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
BRP-041-03
Dec 9, 2030
Enoxbicare-60Enoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
BRP-040-03
Mar 31, 2037
EnoxdenEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Ellebasy Medicale Group Inc.Importer: Ambica International Corporation
BRP-041-08
Dec 9, 2030
EnoxdenEnoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Ellebasy Medicale Group Inc.Importer: Ambica International Corporation
BRP-040-10
Mar 30, 2037
Enoxfadz 4000Enoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Fadz Pharma Inc.Importer: Ambica International Corporation
BRP-041-17
Dec 9, 2030
Enoxfadz 6000Enoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Fadz Pharma Inc.Importer: Ambica International Corporation
BRP-040-16
Jan 22, 2032
GoxaparinEnoxaparin sodium
2,000 IU Anti-Factor Xa (equivalent to 20 mg)/ 0.2 mL Solution for Injection (IV/SC)Pre-filled Syringe in Mono Blister (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Applied Pharmaceutical Distribution IncImporter: Ambica International Corporation
BRP-063-01
Aug 6, 2037
GoxaparinEnoxaparin Sodium
4000 IU anti-Factor Xa (equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories Ltd.India
Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation
BRP-041-06
Dec 9, 2030
GoxaparinEnoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1)
Rx
Brawn Laboratories LimitedIndia
Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation
BRP-040-06
Mar 31, 2037
HepaclexEnoxaparin Sodium
40 mg/0.4 mL Solution for Injection (SC)0.4 mL USP Type I pre-filled glass syringe with 27G x 1⁄2 inch needle, packed in PVC/paper blister (Box of 6 pre- filled syringe in individual cartons)
Rx
Gland Pharma LimitedIndia
Importer: Endure Medical, Inc.
BRP-089
Jun 4, 2028
HepaclexEnoxaparin Sodium
60 mg/0.6 mL Solution for Injection (SC)0.6 mL in 1 mL USP Type I pre-filled glass syringe. with 27G x 1⁄2 inch needle, packed in PVC/paper blister (Box of 6 pre-filled syringe in individual cartons)
Rx
Gland Pharma LimitedIndia
Endure Medical, Inc.
BR-088
Jun 4, 2028
Isohexane 4000Enoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
GCM Pharmaceutical DealerImporter: Ambica International Corporation
BRP-041-09
Dec 9, 2030
Isohexane 6000Enoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
GCM Pharmaceutical DealerImporter: Ambica International Corporation
BRP-040-11
Jul 14, 2031
Lomoh-40Enoxaparin Sodium
40 mg/0.4 mL Solution for Injection (SC)Clear glass USP type I in pre-filled syringe of 0.4 mL packed in a blister of film PVC clear and foil grid lacquer paper (Box of 1's)
Rx
Emcure Pharmaceuticals Ltd.India
Macropharma Corporation
BR-1099
Jun 30, 2030
Lomoh-60Enoxaparin sodium
60 mg/0.6 mL Solution for Injection (S.C)Clear glass USP type I in pre-filled syringe of 0.6 mL packed in a blister of film PVC clear and foil grid lacquer paper (Box of 1's)
Rx
Emcure Pharmaceuticals LimitedIndia
Macropharma Corporation
BR-1098
Jun 30, 2030
NeoxaparinEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Neo Care PhilippinesImporter: Ambica International Corporation
BRP-041-18
Dec 9, 2030
NeoxaparinEnoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1)
Rx
Brawn Laboratories LimitedIndia
Neo-Care PhilippinesImporter: Ambica International Corporation
BRP-040-17
Jul 14, 2031
NoneEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Ritemed Phils., Inc.Importer: Ambica International Corporation
BRP-041-22
Dec 9, 2030
NoneEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL pre-filled syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
HealthPrescription, Inc.Importer: Ambica International Corporation
BRP-041-24
Dec 9, 2030
NoneEnoxaparin sodium
6000 IU Anti-Factor Xa (Equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1)
Rx
Brawn Laboratories Ltd.India
Ritemed Phils., Inc.Importer: Ambica International Corporation
BRP-040-20
Apr 16, 2037
NoneEnoxaparin sodium
6000 IU Anti-factor Xa (equivalent to 60mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
HealthPrescription, Inc.Importer: Ambica International Corporation
BRP-040-21
Mar 6, 2037
NoxaclaneEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Decano Drug Distribution ServicesImporter: Ambica International Corporation
BRP-041-16
Dec 9, 2030
NoxaclaneEnoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1)
Rx
Brawn Laboratories LimitedIndia
Decano Drug Distribution ServicesImporter: Ambica International Corporation
BRP-040-15
Jul 14, 2031
Noxadium 4000Enoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe X 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Central West Medicale Inc.Importer: Ambica International Corporation
BRP-041-01
Dec 9, 2030
Noxadium 6000Enoxaparin sodium
6000 IU Anti-factor Xa (equivalent to 60mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Central West Medicale Inc.Importer: Ambica International Corporation
BRP-040
Mar 6, 2037
NoxeverEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Pharma King DistributorImporter: Ambica International Corporation
BRP-041-23
Dec 9, 2030
Noxhart 4000Enoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Belasram Farma TradingImporter: Ambica International Corporation
BRP-041-11
Dec 9, 2030
Noxhart 6000Enoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Belasram Farma TradingImporter: Ambica International Corporation
BRP-040-13
Jul 14, 2031
NoxprivexEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Sonchel Pharma DistributorsImporter: Ambica International Corporation
BRP-041-04
Dec 9, 2030
NoxprivexEnoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Sonchel Pharma DistributorsImporter: Ambica International Corporation
BRP-040-04
Mar 31, 2037
OlxarinEnoxaparin sodium
4000 IU/0.4 mL (40 mg/0.4 mL) Solution for Injection (SC)0.4 mL Borosilicate Glass Pre-filled Syringe with Rubber Stopper and Plunger Rod (Box of 2's)
Rx
Hangzhou Jiuyuan Gene Engineering Co., Ltd.China
Sahar International Trading, Inc.
BRP-098
Feb 25, 2031
OlxarinEnoxaparin sodium
6000 IU/0.6 mL (60 mg/0.6 mL) Solution for Injection (SC)0.6 mL Borosilicate Glass Pre-filled Syringe with Rubber Stopper and Plunger Rod (Box of 2's)
Rx
Hangzhou Jiuyuan Gene Engineering Co., Ltd.China
Sahar International Trading, Inc.
BRP-097
Feb 11, 2031
RifoxaneEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Rifemedica CorporationImporter: Ambica International Corporation
BRP-041-02
Dec 9, 2030
RifoxaneEnoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1)
Rx
Brawn Laboratories LimitedIndia
Rifemedica CorporationImporter: Ambica International Corporation
BRP-040-01
Apr 16, 2037
SanovinceEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Sanoviz Pharmaceutical Products TradingImporter: Ambica International Corporation
BRP-041-10
Dec 9, 2030
SanovinceEnoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1)
Rx
Brawn Laboratories LimitedIndia
Sanoviz Pharmaceutical Products TradingImporter: Ambica International Corporation
BRP-040-07
Mar 31, 2037
SenorinEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Starpharm, Inc.Importer: Ambica International Corporation
BRP-041-12
Dec 9, 2030
SenorinEnoxaparin
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Starpharm, Inc.Importer: Ambica International Corporation
BRP-040-09
Jul 15, 2037
TamparinEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
BRP-041-15
Dec 9, 2030
TamparinEnoxaparin sodium
6000 IU Anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1)
Rx
Brawn Laboratories LimitedIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
BRP-040-08
Mar 31, 2037
VintrenoxEnoxaparin sodium
4000 IU Anti-Factor Xa (Equivalent to 40 mg) / 0.4 mL Solution for Injection (SC)1 mL Pre-filled Syringe x 0.4 mL (Box of 1 Blister Pack)
Rx
Brawn Laboratories LimitedIndia
Vintel Med EnterprisesImporter: Ambica International Corporation
BRP-041-05
Dec 9, 2030
VintrenoxEnoxaparin sodium
6000 IU anti-Factor Xa (equivalent to 60 mg)/0.6 mL Solution for Injection (SC)1 mL pre-filled syringe in a blister pack x 0.6 mL (Box of 1's)
Rx
Brawn Laboratories LimitedIndia
Vintel Med EnterprisesImporter: Ambica International Corporation
BRP-040-02
Jul 20, 2037

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Lovenox is a clear, colorless to pale-yellow solution available in two concentrations. 100 mg/mL Concentration – Single-Dose Prefilled Syringes 30 mg/0.3 mL, 40 mg/0.4 mL – Single-Dose Graduated Prefilled Syringes 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL – Multiple-Dose Vial 300 mg/3 mL 150 mg/mL Concentration – Single-Dose Graduated Prefilled Syringes 120 mg/0.8 mL, 150 mg/1 mL 100 mg/mL concentration (3): Single-dose prefilled syringes: 30 mg/0.3 mL, 40 mg/0.4 mL Single-dose graduated prefilled syringes: 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL Multiple-dose vial: 300 mg/3 mL 150 mg/mL concentration (3): Single-dose graduated prefilled syringes: 120 mg/0.8 mL, 150 mg/1 mL

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Increased Risk of Hemorrhage: Monitor for signs of bleeding. (5.1, 5.2, 5.3)
  • Risk of Heparin-Induced Thrombocytopenia with or without Thrombosis. (5.4)
  • Thrombocytopenia: Monitor platelet count closely. (5.5)
  • Interchangeability with other heparins: Do not exchange with heparin or other LMWHs. (5.6)
  • Increased Risk of Thrombosis in Pregnant Women with Mechanical Prosthetic Heart Valves: Women and their fetuses may be at increased risk. Monitor more frequently and adjust dosage as needed. (5.7)
5.1 Increased Risk of Hemorrhage

5.1 Increased Risk of Hemorrhage Cases of epidural or spinal hemorrhage and subsequent hematomas have been reported with the use of Lovenox and epidural or spinal anesthesia/analgesia or spinal puncture procedures, resulting in long-term or permanent paralysis. The risk of these events is higher with the use of postoperative indwelling epidural catheters, with the concomitant use of additional drugs affecting hemostasis such as NSAIDs, with traumatic or repeated epidural or spinal puncture, or in patients with a history of spinal surgery or spinal deformity [see Boxed Warning, Adverse Reactions (6.2) and Drug Interactions (7)].

To reduce the potential risk of bleeding associated with the concurrent use of Lovenox and epidural or spinal anesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of Lovenox [see Clinical Pharmacology (12.3)]. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of Lovenox is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.

Placement or removal of a catheter should be delayed for at least 12 hours after administration of lower doses (30 mg once or twice daily or 40 mg once daily) of Lovenox and at least 24 hours after the administration of higher doses (0.75 mg/kg twice daily, 1 mg/kg twice daily, or 1.5 mg/kg once daily) of Lovenox. Anti-Xa levels are still detectable at these time points, and these delays are not a guarantee that neuraxial hematoma will be avoided.

Patients receiving the 0.75 mg/kg twice-daily dose or the 1 mg/kg twice-daily dose should not receive the second Lovenox dose in the twice-daily regimen to allow a longer delay before catheter placement or removal. Likewise, although a specific recommendation for timing of a subsequent Lovenox dose after catheter removal cannot be made, consider delaying this next dose for at least four hours, based on a benefit-risk assessment considering both the risk for thrombosis and the risk for bleeding in the context of the procedure and patient risk factors.

For patients with creatinine clearance <30 mL/minute, additional considerations are necessary because elimination of Lovenox is more prolonged; consider doubling the timing of removal of a catheter, at least 24 hours for the lower prescribed dose of Lovenox (30 mg once daily) and at least 48 hours for the higher dose (1 mg/kg/day) [see Clinical Pharmacology (12.3)]. Should the physician decide to administer anticoagulation in the context of epidural or spinal anesthesia/analgesia or lumbar puncture, frequent monitoring must be exercised to detect any signs and symptoms of neurological impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel and/or bladder dysfunction.

Instruct patients to report immediately if they experience any of the above signs or symptoms. If signs or symptoms of spinal hematoma are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae. Use Lovenox with extreme caution in conditions with increased risk of hemorrhage, such as bacterial endocarditis, congenital or acquired bleeding disorders, active ulcerative and angiodysplastic gastrointestinal disease, hemorrhagic stroke, or shortly after brain, spinal, or ophthalmological surgery, or in patients treated concomitantly with platelet inhibitors.

Major hemorrhages including retroperitoneal and intracranial bleeding have been reported. Some of these cases have been fatal. Bleeding can occur at any site during therapy with Lovenox. An unexplained fall in hematocrit or blood pressure should lead to a search for a bleeding site.

5.2 Increased Risk of Bleeding following Percutaneous Coronary Revascularization Procedures

5.2 Increased Risk of Bleeding following Percutaneous Coronary Revascularization Procedures To minimize the risk of bleeding following the vascular instrumentation during the treatment of unstable angina, non–Q-wave myocardial infarction and acute ST-segment elevation myocardial infarction, adhere precisely to the intervals recommended between Lovenox doses. It is important to achieve hemostasis at the puncture site after PCI.

In case a closure device is used, the sheath can be removed immediately. If a manual compression method is used, sheath should be removed 6 hours after the last intravenous/subcutaneous Lovenox. If the treatment with Lovenox is to be continued, the next scheduled dose should be given no sooner than 6 to 8 hours after sheath removal.

The site of the procedure should be observed for signs of bleeding or hematoma formation [see Dosage and Administration (2.1)].

5.3 Increased Risk of Bleeding in Patients with Concomitant Medical Conditions

5.3 Increased Risk of Bleeding in Patients with Concomitant Medical Conditions Lovenox should be used with care in patients with a bleeding diathesis, uncontrolled arterial hypertension or a history of recent gastrointestinal ulceration, diabetic retinopathy, renal dysfunction and hemorrhage.

5.4 Risk of Heparin-Induced

5.4 Risk of Heparin-Induced Thrombocytopenia with or without Thrombosis Lovenox may cause heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITTS). HITTS may lead to organ infarction, limb ischemia, or death. Monitor thrombocytopenia of any degree closely. Use of Lovenox in patients with a history of immune-mediated HIT within the past 100 days or in the presence of circulating antibodies is contraindicated [see Contraindications (4)].

Circulating antibodies may persist for several years. Only use Lovenox in patients with a history of HIT if more than 100 days have elapsed since the prior HIT episode and no circulating antibodies are present. Because HIT may still occur in these circumstances, the decision to use Lovenox in such a case must be made only after a careful benefit-risk assessment and after non-heparin alternative treatments are considered.

5.5 Thrombocytopenia

5.5 Thrombocytopenia Thrombocytopenia can occur with the administration of Lovenox. Moderate thrombocytopenia (platelet counts between 100,000/mm 3 and 50,000/mm 3) occurred at a rate of 1.3% in patients given Lovenox, 1.2% in patients given heparin, and 0.7% in patients given placebo in clinical trials. Platelet counts less than 50,000/mm 3 occurred at a rate of 0.1% in patients given Lovenox, in 0.2% of patients given heparin, and 0.4% of patients given placebo in the same trials.

Thrombocytopenia of any degree should be monitored closely. If the platelet count falls below 100,000/mm 3, Lovenox should be discontinued.

5.6 Interchangeability

5.6 Interchangeability with other Heparins Lovenox cannot be used interchangeably (unit for unit) with heparin or other low molecular weight heparins as they differ in manufacturing process, molecular weight distribution, anti-Xa and anti-IIa activities, units, and dosage. Each of these medicines has its own instructions for use.

5.7 Increased Risk of Thrombosis in Pregnant Women with Mechanical Prosthetic Heart Valves Use

5.7 Increased Risk of Thrombosis in Pregnant Women with Mechanical Prosthetic Heart Valves Use of Lovenox for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves may result in valve thrombosis. In a clinical study of pregnant women with mechanical prosthetic heart valves given Lovenox (1 mg/kg twice daily) to reduce the risk of thromboembolism, 2 of 8 women developed clots resulting in blockage of the valve and leading to maternal and fetal death.

No patients in the heparin/warfarin group (0 of 4 women) died. There also have been isolated postmarketing reports of valve thrombosis in pregnant women with mechanical prosthetic heart valves while receiving Lovenox for thromboprophylaxis. Women with mechanical prosthetic heart valves may be at higher risk for thromboembolism during pregnancy and, when pregnant, have a higher rate of fetal loss from stillbirth, spontaneous abortion, and premature delivery.

Therefore, frequent monitoring of peak and trough anti-Factor Xa levels, and adjusting of dosage may be needed [see Use in Specific Populations (8.6)].

5.8 Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

5.8 Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative Lovenox multiple-dose vials are not approved for use in neonates or infants. Serious and fatal adverse reactions including "gasping syndrome" can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including Lovenox multiple-dose vials.

The "gasping syndrome" is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known (Lovenox multiple-dose vials contain 15 mg of benzyl alcohol per mL) [see Use in Specific Populations (8.4)].

Because benzyl alcohol may cross the placenta, if anticoagulation with Lovenox is needed during pregnancy, use the preservative-free formulations where possible [see Use in Specific Populations (8.1)].

Drug interactions

Drug or classSeverityEffectWhat to do
Anticoagulants, antiplatelets incl. aspirin and salicylates, NSAIDs (incl. ketorolac), dipyridamoleAdjust or monitorHigher bleeding risk.Stop these before starting enoxaparin when possible; if essential, monitor closely (clinical and laboratory).

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Whenever possible, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of Lovenox therapy. These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.

If coadministration is essential, conduct close clinical and laboratory monitoring [see Warnings and Precautions (5.1)]. Discontinue agents which may enhance hemorrhage risk prior to initiation of Lovenox or conduct close clinical and laboratory monitoring. (2.6, 7)

Adverse reactions

Common

  • Bleeding, anemia, thrombocytopenia, raised aminotransferases, diarrhea, nausea, ecchymosis, fever, edema, dyspnea, confusion, injection-site pain (>1%)

Serious

  • Spinal/epidural hematoma with neuraxial anesthesia or puncture (boxed warning)
  • Major hemorrhage
  • Heparin-induced thrombocytopenia (HIT) with or without thrombosis
  • Thrombocytopenia
  • Valve thrombosis in pregnant women with mechanical heart valves
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following serious adverse reactions are also discussed in other sections of the labeling: Spinal/epidural hematomas [see Boxed Warning and Warnings and Precautions (5.1)] Increased Risk of Hemorrhage [see Warnings and Precautions (5.1)] Thrombocytopenia [see Warnings and Precautions (5.5)] Most common adverse reactions (>1%) were bleeding, anemia, thrombocytopenia, elevation of serum aminotransferase, diarrhea, nausea, ecchymosis, fever, edema, peripheral edema, dyspnea, confusion, and injection site pain. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. During clinical development for the approved indications, 15,918 patients were exposed to Lovenox.

These included 1,228 for prophylaxis of deep vein thrombosis following abdominal surgery in patients at risk for thromboembolic complications, 1,368 for prophylaxis of deep vein thrombosis following hip or knee replacement surgery, 711 for prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness, 1,578 for prophylaxis of ischemic complications in unstable angina and non–Q-wave myocardial infarction, 10,176 for treatment of acute ST-elevation myocardial infarction, and 857 for treatment of deep vein thrombosis with or without pulmonary embolism. Lovenox doses in the clinical trials for prophylaxis of deep vein thrombosis following abdominal or hip or knee replacement surgery or in medical patients with severely restricted mobility during acute illness ranged from 40 mg subcutaneously once daily to 30 mg subcutaneously twice daily.

In the clinical studies for prophylaxis of ischemic complications of unstable angina and non–Q-wave myocardial infarction doses were 1 mg/kg every 12 hours and in the clinical studies for treatment of acute ST-segment elevation myocardial infarction Lovenox doses were a 30 mg intravenous bolus followed by 1 mg/kg every 12 hours subcutaneously. Hemorrhage The following rates of major bleeding events have been reported during clinical trials with Lovenox (see Tables 2 to 7).

Table 2: Major Bleeding Episodes following Abdominal and Colorectal Surgery Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal, intraocular, and intracranial hemorrhages were always considered major.

Dosing Regimen Indications Lovenox 40 mg daily subcutaneously Heparin 5000 U q8h subcutaneously Abdominal Surgery n=555 23 (4%) n=560 16 (3%) Colorectal Surgery n=673 28 (4%) n=674 21 (3%) Table 3: Major Bleeding Episodes following Hip or Knee Replacement Surgery Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and intracranial hemorrhages were always considered major.

In the knee replacement surgery trials, intraocular hemorrhages were also considered major hemorrhages. Dosing Regimen Indications Lovenox 40 mg daily subcutaneously Lovenox 30 mg q12h subcutaneously Heparin 15,000 U/24h subcutaneously Hip Replacement Surgery without Extended Prophylaxis Lovenox 30 mg every 12 hours subcutaneously initiated 12 to 24 hours after surgery and continued for up to 14 days after surgery – n=786 31 (4%) n=541 32 (6%) Hip Replacement Surgery with Extended Prophylaxis – – – Peri-operative Period Lovenox 40 mg subcutaneously once a day initiated up to 12 hours prior to surgery and continued for up to 7 days after surgery n=288 4 (2%) – – Extended Prophylaxis Period Lovenox 40 mg subcutaneously once a day for up to 21 days after discharge n=221 0 (0%) – – Knee Replacement Surgery without Extended Prophylaxis – n=294 3 (1%) n=225 3 (1%) NOTE: At no time point were the 40 mg once a day pre-operative and the 30 mg every 12 hours postoperative hip replacement surgery prophylactic regimens compared in clinical trials.

Injection site hematomas during the extended prophylaxis period after hip replacement surgery occurred in 9% of the Lovenox patients versus 1.8% of the placebo patients. Table 4: Major Bleeding Episodes in Medical Patients with Severely Restricted Mobility during Acute Illness Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, (2) if the hemorrhage caused a decrease in hemoglobin of ≥2 g/dL or transfusion of 2 or more units of blood products.

Retroperitoneal and intracranial hemorrhages were always considered major although none were reported during the trial. Dosing Regimen Indication Lovenox The rates represent major bleeding on study medication up to 24 hours after last dose. 20 mg daily subcutaneously Lovenox 40 mg daily subcutaneously Placebo Medical Patients during Acute Illness n=351 1 (<1%) n=360 3 (<1%) n=362 2 (<1%) Table 5: Major Bleeding Episodes in Deep Vein Thrombosis with or without Pulmonary Embolism Treatment Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥2 g/dL or transfusion of 2 or more units of blood products.

Retroperitoneal, intraocular, and intracranial hemorrhages were always considered major. Dosing Regimen All patients also received warfarin sodium (dose-adjusted according to PT to achieve an INR of 2.0 to 3.0) commencing within 72 hours of Lovenox or standard heparin therapy and continuing for up to 90 days. Indication Lovenox 1.5 mg/kg daily subcutaneously Lovenox 1 mg/kg q12h subcutaneously Heparin aPTT Adjusted Intravenous Therapy Treatment of DVT and PE n=298 5 (2%) n=559 9 (2%) n=554 9 (2%) Table 6: Major Bleeding Episodes in Unstable Angina and Non–Q-Wave Myocardial Infarction Dosing Regimen Indication Lovenox The rates represent major bleeding on study medication up to 12 hours after dose. 1 mg/kg q12h subcutaneously Heparin aPTT Adjusted Intravenous Therapy Unstable Angina and Non–Q-Wave MI Aspirin therapy was administered concurrently (100 to 325 mg per day)., Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease by ≥3 g/dL or transfusion of 2 or more units of blood products.

Intraocular, retroperitoneal, and intracranial hemorrhages were always considered major. n=1578 17 (1%) n=1529 18 (1%) Table 7: Major Bleeding Episodes in Acute ST-Segment Elevation Myocardial Infarction Dosing Regimen Indication Lovenox The rates represent major bleeding (including ICH) up to 30 days. Initial 30 mg intravenous bolus followed by 1 mg/kg q12h subcutaneously Heparin aPTT Adjusted Intravenous Therapy Acute ST-Segment Elevation Myocardial Infarction n=10176 n (%) n=10151 n (%) Major bleeding (including ICH) Bleedings were considered major if the hemorrhage caused a significant clinical event associated with a hemoglobin decrease by ≥5 g/dL.

ICH were always considered major. 211 (2.1) 138 (1.4) Intracranial hemorrhages (ICH) 84 (0.8) 66 (0.7) Elevations of Serum Aminotransferases Asymptomatic increases in aspartate (AST [SGOT]) and alanine (ALT [SGPT]) aminotransferase levels greater than three times the upper limit of normal of the laboratory reference range have been reported in up to 6.1% and 5.9% of patients, respectively, during treatment with Lovenox. Since aminotransferase determinations are important in the differential diagnosis of myocardial infarction, liver disease, and pulmonary emboli, elevations that might be caused by drugs like Lovenox should be interpreted with caution.

Local Reactions Local irritation, pain, hematoma, ecchymosis, and erythema may follow subcutaneous injection of Lovenox. Adverse Reactions in Patients Receiving Lovenox for Prophylaxis or Treatment of DVT, PE Other adverse reactions that were thought to be possibly or probably related to treatment with Lovenox, heparin, or placebo in clinical trials with patients undergoing hip or knee replacement surgery, abdominal or colorectal surgery, or treatment for DVT and that occurred at a rate of at least 2% in the Lovenox group, are provided below (see Tables 8 to 11).

Table 8: Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Patients Undergoing Abdominal or Colorectal Surgery Dosing Regimen Lovenox 40 mg daily subcutaneously n=1228 % Heparin 5000 U q8h subcutaneously n=1234 % Adverse Reaction Severe Total Severe Total Hemorrhage <1 7 <1 6 Anemia <1 3 <1 3 Ecchymosis 0 3 0 3 Table 9: Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Patients Undergoing Hip or Knee Replacement Surgery Dosing Regimen Lovenox 40 mg daily subcutaneously Lovenox 30 mg q12h subcutaneously Heparin 15,000 U/24h subcutaneously Placebo q12h subcutaneously Peri-operative Period Extended Prophylaxis Period n=288 Data represent Lovenox 40 mg subcutaneously once a day initiated up to 12 hours prior to surgery in 288 hip replacement surgery patients who received Lovenox peri-operatively in an unblinded fashion in one clinical trial. % n=131 Data represent Lovenox 40 mg subcutaneously once a day given in a blinded fashion as extended prophylaxis at the end of the peri-operative period in 131 of the original 288 hip replacement surgery patients for up to 21 days in one clinical trial. % n=1080 % n=766 % n=115 % Adverse Reaction Severe Total Severe Total Severe Total Severe Total Severe Total Fever 0 8 0 0 <1 5 <1 4 0 3 Hemorrhage <1 13 0 5 <1 4 1 4 0 3 Nausea – – – <1 3 <1 2 0 2 Anemia 0 16 0 <2 <1 2 2 5 <1 7 Edema – – – – <1 2 <1 2 0 2 Peripheral edema 0 6 0 0 <1 3 <1 4 0 3 Table 10: Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Medical Patients with Severely Restricted Mobility during Acute Illness Dosing Regimen Adverse Reaction Lovenox 40 mg daily subcutaneously n=360 % Placebo daily subcutaneously n=362 % Dyspnea 3.3 5.2 Thrombocytopenia 2.8 2.8 Confusion 2.2 1.1 Diarrhea 2.2 1.7 Nausea 2.5 1.7 Table 11: Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Patients Undergoing Treatment of Deep Vein Thrombosis with or without Pulmonary Embolism Dosing Regimen Lovenox 1.5 mg/kg daily subcutaneously n=298 % Lovenox 1 mg/kg q12h subcutaneously n=559 % Heparin aPTT Adjusted Intravenous Therapy n=544 % Adverse Reaction Severe Total Severe Total Severe Total Injection Site Hemorrhage 0 5 0 3 <1 <1 Injection Site Pain 0 2 0 2 0 0 Hematuria 0 2 0 <1 <1 2 Adverse Events in Lovenox-Treated Patients with Unstable Angina or Non–Q-Wave Myocardial Infarction Non-hemorrhagic clinical events reported to be related to Lovenox therapy occurred at an incidence of ≤1%. Non-major hemorrhagic events, primarily injection site ecchymosis and hematomas, were more frequently reported in patients treated with subcutaneous Lovenox than in patients treated with intravenous heparin.

Serious adverse events with Lovenox or heparin in a clinical trial in patients with unstable angina or non–Q-wave myocardial infarction that occurred at a rate of at least 0.5% in the Lovenox group are provided below (see Table 12). Table 12: Serious Adverse Events Occurring at ≥0.5% Incidence in Lovenox-Treated Patients with Unstable Angina or Non–Q-Wave Myocardial Infarction Dosing Regimen Lovenox 1 mg/kg q12h subcutaneously Heparin aPTT Adjusted Intravenous Therapy Adverse Event n=1578 n (%) n=1529 n (%) Atrial fibrillation 11 (0.70) 3 (0.20) Heart failure 15 (0.95) 11 (0.72) Lung edema 11 (0.70) 11 (0.72) Pneumonia 13 (0.82) 9 (0.59) Adverse Reactions in Lovenox-Treated Patients with Acute ST-Segment Elevation Myocardial Infarction In a clinical trial in patients with acute ST-segment elevation myocardial infarction, thrombocytopenia occurred at a rate of 1.5%.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of Lovenox. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. There have been reports of epidural or spinal hematoma formation with concurrent use of Lovenox and spinal/epidural anesthesia or spinal puncture.

The majority of patients had a postoperative indwelling epidural catheter placed for analgesia or received additional drugs affecting hemostasis such as NSAIDs. Many of the epidural or spinal hematomas caused neurologic injury, including long-term or permanent paralysis. Local reactions at the injection site (e.g. nodules, inflammation, oozing), systemic allergic reactions (e.g. pruritus, urticaria, anaphylactic/anaphylactoid reactions including shock), vesiculobullous rash, cases of hypersensitivity cutaneous vasculitis, purpura, skin necrosis (occurring at either the injection site or distant from the injection site), thrombocytosis, and thrombocytopenia with thrombosis [see Warnings and Precautions (5.5)] have been reported.

Cases of hyperkalemia have been reported. Most of these reports occurred in patients who also had conditions that tend toward the development of hyperkalemia (e.g., renal dysfunction, concomitant potassium-sparing drugs, administration of potassium, hematoma in body tissues). Very rare cases of hyperlipidemia have also been reported, with one case of hyperlipidemia, with marked hypertriglyceridemia, reported in a diabetic pregnant woman; causality has not been determined.

Cases of headache, hemorrhagic anemia, eosinophilia, alopecia, hepatocellular and cholestatic liver injury have been reported. Osteoporosis has also been reported following long-term therapy.

Adverse reaction frequency tables (US label) US FDA label
Table 2: Major Bleeding Episodes following Abdominal and Colorectal SurgeryBleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal, intraocular, and intracranial hemorrhages were always considered major.
Dosing Regimen
IndicationsLovenox 40 mg daily subcutaneouslyHeparin 5000 U q8h subcutaneously
Abdominal Surgeryn=555 23 (4%)n=560 16 (3%)
Colorectal Surgeryn=673 28 (4%)n=674 21 (3%)
Table 3: Major Bleeding Episodes following Hip or Knee Replacement SurgeryBleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and intracranial hemorrhages were always considered major. In the knee replacement surgery trials, intraocular hemorrhages were also considered major hemorrhages.
Dosing Regimen
IndicationsLovenox 40 mg daily subcutaneouslyLovenox 30 mg q12h subcutaneouslyHeparin 15,000 U/24h subcutaneously
Hip Replacement Surgery without Extended ProphylaxisLovenox 30 mg every 12 hours subcutaneously initiated 12 to 24 hours after surgery and continued for up to 14 days after surgery–n=786 31 (4%)n=541 32 (6%)
Hip Replacement Surgery with Extended Prophylaxis–––
Peri-operative PeriodLovenox 40 mg subcutaneously once a day initiated up to 12 hours prior to surgery and continued for up to 7 days after surgeryn=288 4 (2%)––
Extended Prophylaxis PeriodLovenox 40 mg subcutaneously once a day for up to 21 days after dischargen=221 0 (0%)––
Knee Replacement Surgery without Extended Prophylaxis–n=294 3 (1%)n=225 3 (1%)
Table 4: Major Bleeding Episodes in Medical Patients with Severely Restricted Mobility during Acute IllnessBleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, (2) if the hemorrhage caused a decrease in hemoglobin of ≥2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and intracranial hemorrhages were always considered major although none were reported during the trial.
Dosing Regimen
IndicationLovenoxThe rates represent major bleeding on study medication up to 24 hours after last dose. 20 mg daily subcutaneouslyLovenox 40 mg daily subcutaneouslyPlacebo
Medical Patients during Acute Illnessn=351 1 (<1%)n=360 3 (<1%)n=362 2 (<1%)
Table 5: Major Bleeding Episodes in Deep Vein Thrombosis with or without Pulmonary Embolism TreatmentBleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal, intraocular, and intracranial hemorrhages were always considered major.
Dosing RegimenAll patients also received warfarin sodium (dose-adjusted according to PT to achieve an INR of 2.0 to 3.0) commencing within 72 hours of Lovenox or standard heparin therapy and continuing for up to 90 days.
IndicationLovenox 1.5 mg/kg daily subcutaneouslyLovenox 1 mg/kg q12h subcutaneouslyHeparin aPTT Adjusted Intravenous Therapy
Treatment of DVT and PEn=298 5 (2%)n=559 9 (2%)n=554 9 (2%)
Table 6: Major Bleeding Episodes in Unstable Angina and Non–Q-Wave Myocardial Infarction
Dosing Regimen
IndicationLovenoxThe rates represent major bleeding on study medication up to 12 hours after dose. 1 mg/kg q12h subcutaneouslyHeparin aPTT Adjusted Intravenous Therapy
Unstable Angina and Non–Q-Wave MIAspirin therapy was administered concurrently (100 to 325 mg per day).,Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease by ≥3 g/dL or transfusion of 2 or more units of blood products. Intraocular, retroperitoneal, and intracranial hemorrhages were always considered major.n=1578 17 (1%)n=1529 18 (1%)
Table 7: Major Bleeding Episodes in Acute ST-Segment Elevation Myocardial Infarction
Dosing Regimen
IndicationLovenoxThe rates represent major bleeding (including ICH) up to 30 days. Initial 30 mg intravenous bolus followed by 1 mg/kg q12h subcutaneouslyHeparin aPTT Adjusted Intravenous Therapy
Acute ST-Segment Elevation Myocardial Infarctionn=10176 n (%)n=10151 n (%)
Major bleeding (including ICH)Bleedings were considered major if the hemorrhage caused a significant clinical event associated with a hemoglobin decrease by ≥5 g/dL. ICH were always considered major.211 (2.1)138 (1.4)
Intracranial hemorrhages (ICH)84 (0.8)66 (0.7)
Table 8: Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Patients Undergoing Abdominal or Colorectal Surgery
Dosing Regimen
Lovenox 40 mg daily subcutaneously n=1228 %Heparin 5000 U q8h subcutaneously n=1234 %
Adverse ReactionSevereTotalSevereTotal
Hemorrhage<17<16
Anemia<13<13
Ecchymosis0303
Table 9: Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Patients Undergoing Hip or Knee Replacement Surgery
Dosing Regimen
Lovenox 40 mg daily subcutaneouslyLovenox 30 mg q12h subcutaneouslyHeparin 15,000 U/24h subcutaneouslyPlacebo q12h subcutaneously
Peri-operative PeriodExtended Prophylaxis Period
n=288Data represent Lovenox 40 mg subcutaneously once a day initiated up to 12 hours prior to surgery in 288 hip replacement surgery patients who received Lovenox peri-operatively in an unblinded fashion in one clinical trial. %n=131Data represent Lovenox 40 mg subcutaneously once a day given in a blinded fashion as extended prophylaxis at the end of the peri-operative period in 131 of the original 288 hip replacement surgery patients for up to 21 days in one clinical trial. %n=1080 %n=766 %n=115 %
Adverse ReactionSevereTotalSevereTotalSevereTotalSevereTotalSevereTotal
Fever0800<15<1403
Hemorrhage<11305<141403
Nausea–––<13<1202
Anemia0160<2<1225<17
Edema––––<12<1202
Peripheral edema0600<13<1403
Table 10: Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Medical Patients with Severely Restricted Mobility during Acute Illness
Dosing Regimen
Adverse ReactionLovenox 40 mg daily subcutaneously n=360 %Placebo daily subcutaneously n=362 %
Dyspnea3.35.2
Thrombocytopenia2.82.8
Confusion2.21.1
Diarrhea2.21.7
Nausea2.51.7
Table 11: Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Patients Undergoing Treatment of Deep Vein Thrombosis with or without Pulmonary Embolism
Dosing Regimen
Lovenox 1.5 mg/kg daily subcutaneously n=298 %Lovenox 1 mg/kg q12h subcutaneously n=559 %Heparin aPTT Adjusted Intravenous Therapy n=544 %
Adverse ReactionSevereTotalSevereTotalSevereTotal
Injection Site Hemorrhage0503<1<1
Injection Site Pain020200
Hematuria020<1<12
Table 12: Serious Adverse Events Occurring at ≥0.5% Incidence in Lovenox-Treated Patients with Unstable Angina or Non–Q-Wave Myocardial Infarction
Dosing Regimen
Lovenox 1 mg/kg q12h subcutaneouslyHeparin aPTT Adjusted Intravenous Therapy
Adverse Eventn=1578 n (%)n=1529 n (%)
Atrial fibrillation11 (0.70)3 (0.20)
Heart failure15 (0.95)11 (0.72)
Lung edema11 (0.70)11 (0.72)
Pneumonia13 (0.82)9 (0.59)

Monitoring parameters

  • Signs of bleeding in all kidney impairment; platelet count (heparin-induced thrombocytopenia); potassium (hyperkalemia reported in renal failure) (label). Low body weight (women <45 kg, men <57 kg) raises exposure: observe closely for bleeding (label). Kidney
  • Screen for bleeding disorders before starting
  • Platelet count, hemoglobin and signs of bleeding
  • Kidney function (creatinine clearance) for dose selection
  • Anti-factor Xa levels: see approved kidney guidance for dialysis
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Placental transfer of enoxaparin was observed in the animal studies. Human data from a retrospective cohort study, which included 693 live births, suggest that enoxaparin does not increase the risk of major developmental abnormalities (see Data). Based on animal data, Lovenox is not predicted to increase the risk of major developmental abnormalities (see Data).

Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations Pregnancy alone confers an increased risk for thromboembolism that is even higher for women with thromboembolic disease and certain high risk pregnancy conditions. While not adequately studied, pregnant women with mechanical prosthetic heart valves may be at even higher risk for thrombosis [see Warnings and Precautions (5.7) and Use in Specific Populations (8.6)].

Pregnant women with thromboembolic disease, including those with mechanical prosthetic heart valves and those with inherited or acquired thrombophilias, have an increased risk of other maternal complications and fetal loss regardless of the type of anticoagulant used. All patients receiving anticoagulants, including pregnant women, are at risk for bleeding.

Pregnant women receiving Lovenox should be carefully monitored for evidence of bleeding or excessive anticoagulation. Consideration for use of a shorter acting anticoagulant should be specifically addressed as delivery approaches [see Boxed Warning]. Hemorrhage can occur at any site and may lead to death of mother and/or fetus.

Pregnant women should be apprised of the potential hazard to the fetus and the mother if Lovenox is administered during pregnancy. It is not known if monitoring of anti-Factor Xa activity and dose adjustment (by weight or anti-Factor Xa activity) of Lovenox affect the safety and the efficacy of the drug during pregnancy.

Cases of "gasping syndrome" have occurred in premature infants when large amounts of benzyl alcohol have been administered (99–405 mg/kg/day). The multiple-dose vial of Lovenox contains 15 mg benzyl alcohol per 1 mL as a preservative [see Warnings and Precautions (5.8)]. Data Human data There are no adequate and well-controlled studies in pregnant women.

A retrospective study reviewed the records of 604 women who used Lovenox during pregnancy. A total of 624 pregnancies resulted in 693 live births. There were 72 hemorrhagic events (11 serious) in 63 women. There were 14 cases of neonatal hemorrhage. Major congenital anomalies in live births occurred at rates (2.5%) similar to background rates.

There have been postmarketing reports of fetal death when pregnant women received Lovenox. Causality for these cases has not been determined. Insufficient data, the underlying disease, and the possibility of inadequate anticoagulation complicate the evaluation of these cases. A clinical study using Lovenox in pregnant women with mechanical prosthetic heart valves has been conducted [see Warnings and Precautions (5.7)].

Animal data Teratology studies have been conducted in pregnant rats and rabbits at subcutaneous doses of enoxaparin up to 15 times the recommended human dose (by comparison with 2 mg/kg as the maximum recommended daily dose). There was no evidence of teratogenic effects or fetotoxicity due to enoxaparin. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Mechanism of action

12.1 Mechanism of Action Enoxaparin is a low molecular weight heparin which has antithrombotic properties.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics In humans, enoxaparin given at a dose of 1.5 mg/kg subcutaneously is characterized by a higher ratio of anti-Factor Xa to anti-Factor IIa activity (mean ±SD, 14.0±3.1) (based on areas under anti-Factor activity versus time curves) compared to the ratios observed for heparin (mean ±SD, 1.22±0.13). Increases of up to 1.8 times the control values were seen in the thrombin time (TT) and the activated partial thromboplastin time (aPTT).

Enoxaparin at a 1 mg/kg dose (100 mg/mL concentration), administered subcutaneously every 12 hours to patients in a large clinical trial resulted in aPTT values of 45 seconds or less in the majority of patients (n=1607). A 30 mg intravenous bolus immediately followed by a 1 mg/kg subcutaneous administration resulted in aPTT postinjection values of 50 seconds.

The average aPTT prolongation value on Day 1 was about 16% higher than on Day 4.

Pharmacokinetics

Key PK parameters

BioavailabilityAbout 100% SC (anti-factor Xa)
Time to peakAbout 3 hours (anti-factor Xa, median)
Half-life4.5 hours (single SC dose) to about 7 hours (repeated dosing), anti-factor Xa
Half-life in kidney failure (ESKD) kidneyHemodialysis: elimination rate similar but AUC two-fold higher (single IV dose study; label)
Volume of distributionAbout 4.3 L (anti-factor Xa)
Metabolism (CYP, transporters)Liver desulfation and/or depolymerization to less active fragments
Renal excretion kidneyActive fragments about 10% of the dose; total renal (active and inactive) about 40%
Dialyzability kidneyNot stated in label.
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.

Renal clearance of active fragments represents about 10% of the administered dose and total renal excretion of active and non-active fragments 40% of the dose.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption Pharmacokinetic trials were conducted using the 100 mg/mL formulation. Maximum anti-Factor Xa and anti-thrombin (anti-Factor IIa) activities occur 3 to 5 hours after subcutaneous injection of enoxaparin. Mean peak anti-Factor Xa activity was 0.16 IU/mL (1.58 mcg/mL) and 0.38 IU/mL (3.83 mcg/mL) after the 20 mg and the 40 mg clinically tested subcutaneous doses, respectively.

Mean (n=46) peak anti-Factor Xa activity was 1.1 IU/mL at steady state in patients with unstable angina receiving 1 mg/kg subcutaneously every 12 hours for 14 days. Mean absolute bioavailability of enoxaparin, after 1.5 mg/kg given subcutaneously, based on anti-Factor Xa activity is approximately 100% in healthy subjects.

A 30 mg intravenous bolus immediately followed by 1 mg/kg subcutaneously every 12 hours provided initial peak anti-Factor Xa levels of 1.16 IU/mL (n=16) and average exposure corresponding to 84% of steady-state levels. Steady state is achieved on the second day of treatment. Enoxaparin pharmacokinetics appears to be linear over the recommended dosage ranges [see Dosage and Administration (2)].

After repeated subcutaneous administration of 40 mg once daily and 1.5 mg/kg once-daily regimens in healthy volunteers, the steady state is reached on day 2 with an average exposure ratio about 15% higher than after a single dose. Steady-state enoxaparin activity levels are well predicted by single-dose pharmacokinetics.

After repeated subcutaneous administration of the 1 mg/kg twice-daily regimen, the steady state is reached from day 4 with mean exposure about 65% higher than after a single dose and mean peak and trough levels of about 1.2 and 0.52 IU/mL, respectively. Based on enoxaparin sodium pharmacokinetics, this difference in steady state is expected and within the therapeutic range.

Although not studied clinically, the 150 mg/mL concentration of enoxaparin sodium is projected to result in anticoagulant activities similar to those of 100 mg/mL and 200 mg/mL concentrations at the same enoxaparin dose. When a daily 1.5 mg/kg subcutaneous injection of enoxaparin sodium was given to 25 healthy male and female subjects using a 100 mg/mL or a 200 mg/mL concentration the following pharmacokinetic profiles were obtained (see Table 13).

Table 13: Pharmacokinetic Parameters Means ±SD at Day 5 and 90% Confidence Interval (CI) of the ratio After 5 Days of 1.5 mg/kg Subcutaneous Once-Daily Doses of Enoxaparin Sodium Using 100 mg/mL or 200 mg/mL Concentrations Concentration Anti-Xa Anti-IIa Heptest aPTT A max (IU/mL or Δ sec) 100 mg/mL 1.37 (±0.23) 0.23 (±0.05) 105 (±17) 19 (±5) 200 mg/mL 1.45 (±0.22) 0.26 (±0.05) 111 (±17) 22 (±7) 90% CI 102%–110% 102%–111% t max Median (range) (h) 100 mg/mL 3 (2–6) 4 (2–5) 2.5 (2–4.5) 3 (2–4.5) 200 mg/mL 3.5 (2–6) 4.5 (2.5–6) 3.3 (2–5) 3 (2–5) AUC (ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%–112% 103%–109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L. Elimination Following intravenous dosing, the total body clearance of enoxaparin is 26 mL/min.

After intravenous dosing of enoxaparin labeled with the gamma-emitter, 99m Tc, 40% of radioactivity and 8 to 20% of anti-Factor Xa activity were recovered in urine in 24 hours. Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing. Significant anti-Factor Xa activity persists in plasma for about 12 hours following a 40 mg subcutaneous once a day dose.

Following subcutaneous dosing, the apparent clearance (CL/F) of enoxaparin is approximately 15 mL/min. Metabolism Enoxaparin sodium is primarily metabolized in the liver by desulfation and/or depolymerization to lower molecular weight species with much reduced biological potency. Renal clearance of active fragments represents about 10% of the administered dose and total renal excretion of active and non-active fragments 40% of the dose.

Special Populations Gender Apparent clearance and A max derived from anti-Factor Xa values following single subcutaneous dosing (40 mg and 60 mg) were slightly higher in males than in females. The source of the gender difference in these parameters has not been conclusively identified; however, body weight may be a contributing factor.

Geriatric Apparent clearance and A max derived from anti-Factor Xa values following single and multiple subcutaneous dosing in geriatric subjects were close to those observed in young subjects. Following once a day subcutaneous dosing of 40 mg enoxaparin, the Day 10 mean area under anti-Factor Xa activity versus time curve (AUC) was approximately 15% greater than the mean Day 1 AUC value [see Dosage and Administration (2.4) and Use in Specific Populations (8.5)].

Renal impairment A linear relationship between anti-Factor Xa plasma clearance and creatinine clearance at steady state has been observed, which indicates decreased clearance of enoxaparin sodium in patients with reduced renal function. Anti-Factor Xa exposure represented by AUC, at steady state, is marginally increased in patients with creatinine clearance 50 to 80 mL/min and patients with creatinine clearance 30 to <50 mL/min after repeated subcutaneous 40 mg once-daily doses.

In patients with severe renal impairment (creatinine clearance <30 mL/min), the AUC at steady state is significantly increased on average by 65% after repeated subcutaneous 40 mg once-daily doses [see Dosage and Administration (2.3) and Use in Specific Populations (8.7)]. Hemodialysis In a single study, elimination rate appeared similar but AUC was two-fold higher than control population, after a single 0.25 or 0.5 mg/kg intravenous dose.

Hepatic impairment Studies with Lovenox in patients with hepatic impairment have not been conducted and the impact of hepatic impairment on the exposure to enoxaparin is unknown. Weight After repeated subcutaneous 1.5 mg/kg once-daily dosing, mean AUC of anti-Factor Xa activity is marginally higher at steady state in obese healthy volunteers (BMI 30–48 kg/m 2) compared to non-obese control subjects, while A max is not increased.

When non–weight-adjusted dosing was administered, it was found after a single-subcutaneous 40 mg dose, that anti-Factor Xa exposure is 52% higher in low-weight women (<45 kg) and 27% higher in low-weight men (<57 kg) when compared to normal weight control subjects [see Use in Specific Populations (8.8)]. Pharmacokinetic Interaction No pharmacokinetic interaction was observed between Lovenox and thrombolytics when administered concomitantly.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Enoxaparin 100 mg/mL, 0.4 mL Pre-filled syringe₱179.89–₱398.00Reference ₱195.60per syringeDPRI procurement range
Enoxaparin 100 mg/mL, 0.6 mL Pre-filled syringe ●₱195.00–₱465.00Reference ₱278.32per syringeDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Enoxaparin (as sodium salt)
PNF listingInj.: 100 mg/mL, 0.2 mL, 0.4 mL and 0.6 mL pre-filled syringe (SC)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Lovenox · Sanofi-Aventis U.S. LLC [US FDA-approved label, version 33, May 28, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5017a927-2a24-4f27-89f9-27c805bf7d59
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  5. Sanofi-Aventis U.S. LLC. (2026). Lovenox (enoxaparin sodium) [Prescribing information; US FDA-approved label, NDA020164, set ID 5017a927-2a24-4f27-89f9-27c805bf7d59, version effective May 28, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5017a927-2a24-4f27-89f9-27c805bf7d59
  6. Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .